Date | 10/9/2013 | 6/24/2014 | 12/9/2014 | 12/31/2014 | 6/8/2015 | 8/19/2015 |
---|---|---|---|---|---|---|
Significant event | Initial diagnosis | MRD Positive | 1st Relapse | Persistent disease | Post-ASCTa | 2nd Relapse |
BM Blast (%) (0–5) | 61 | NA | 5 | 54 | 1 | 25 |
WBC (x109/L) | 2.0 | 5.5 | 4.6 | 2.8 | 5.6 | 2.2 |
PLT (x103/μL) | 88 | 383 | 202 | 79 | 133 | 79 |
HB (g/dL) | 8.3 | 10.8 | 13.3 | 12.9 | 9.1 | 11.4 |
Flow-cytometry analysis | Positiveb | Positive | Positivec | Positived | NA | Positive |
G-Band karyotyping | NAe | NA | 46,XY | Complex | 46,XY | 46,XY |
ETV6-RUNX1/iAMP21 FISH | Positive | Negative | Borderline Negative | Positive | NA | NA |
ETV6-RUNX1 by PCR | NA | NA | NA | Positive | NA | NA |
Treatment | CALGBf | Post- CALGB | Blinatumomab | Hyper-CVADg + Inotuzumab | 50 days Post-ASCT | EPOCHh + Rituxan |